Research Highlights

 

Oki T, Mercier F, Kato H, Jung Y, McDonald TO, Spencer JA, Mazzola MC, van Gastel N, Lin CP, Michor F, Kitamura T, Scadden DT.
Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML.
Nat Commun. 2021 Jan 11;12(1):245. doi: 10.1038/s41467-020-20491-8. PMID: 33431855; PMCID: PMC7801403.

Shen YJ, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd RA, Moschetta M, Manier S, Roccaro AM, Sacco A, Tai YT, Mercier FE, Kawano Y, Su NK, Berrios B, Doench J, Root DE, Michor F, Scadden DT, Ghobrial IM.
Progression signature underlies clonal evolution and dissemination of multiple myeloma.
Blood. 2020 Nov 4:blood.2020005885. doi: 10.1182/blood.2020005885. Epub ahead of print. PMID: 33150374.

Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, Reddy Chilamakuri CS, Papachristou EK, D'Santos C, Anand J, Hinohara K, Li W, McDonald TO, Luoma A, Modiste RJ, Nguyen QD, Michel B, Cejas P, Kadoch C, Jaffe JD, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K.
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Mol Cell. 2020 Jun 18;78(6):1096-1113.e8. doi: 10.1016/j.molcel.2020.04.027. Epub 2020 May 15. PMID: 32416067; PMCID: PMC7306005.

Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K.
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Nat Commun. 2020 May 11;11(1):2350. doi: 10.1038/s41467-020-16170-3. PMID: 32393766; PMCID: PMC7214447.

Brempelis KJ, Cowan CM, Kreuser SA, Labadie KP, Prieskorn BM, Lieberman NAP, Ene CI, Moyes KW, Chinn H, DeGolier KR, Matsumoto LR, Daniel SK, Yokoyama JK, Davis AD, Hoglund VJ, Smythe KS, Balcaitis SD, Jensen MC, Ellenbogen RG, Campbell JS, Pierce RH, Holland EC, Pillarisetty VG, Crane CA.
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
J Immunother Cancer. 2020 Oct;8(2):e001356. doi: 10.1136/jitc-2020-001356. PMID: 33115946; PMCID: PMC7594542.

 

S5 Box

Login Form